Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04977388
PHASE1/PHASE2

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

Sponsor: Stephen G. Kaler, MD

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.

Official title: Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

3

Start Date

2021-07-12

Completion Date

2024-06-29

Last Updated

2026-04-13

Healthy Volunteers

No

Interventions

DRUG

Droxidopa

Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.

OTHER

Placebo

Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.

Locations (1)

Vagelos College of Physicians and Surgeons, Columbia University

New York, New York, United States